SIREN : 493542211
CANCROISSANCE is a French company founded 19 years ago, specialized in the sector Activités des sociétés holding. Based in MIRMANDE (26270), this company of category ETI shows in 2024 a revenue of 2.0 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-02
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|
| Revenue | 1 966 524 € | 1 790 129 € | 1 795 710 € | 1 637 151 € | 1 946 028 € | 1 748 470 € |
| Net income | 5 312 661 € | 57 641 € | 109 602 € | 773 141 € | 512 820 € | 1 256 463 € |
| EBITDA | 136 948 € | 145 056 € | 154 517 € | 94 805 € | 156 631 € | 136 546 € |
| Net margin | 270.2% | 3.2% | 6.1% | 47.2% | 26.4% | 71.9% |
In 2024, CANCROISSANCE achieves revenue of 2.0 M€. Revenue is growing positively over 6 years (CAGR: +1.3%). Vs 2023: +10%. After deducting consumption (0 €), gross margin stands at 2.0 M€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 137 k€, representing 7.0% of revenue. The operating margin remains fragile, requiring cost vigilance. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 5.3 M€, i.e. 270.2% of revenue. This profit can be retained or distributed to shareholders.
1 966 524 €
1 966 524 €
136 948 €
126 788 €
5 312 661 €
7.0%
The debt ratio (= Financial debt / Equity x 100) stands at 153%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 32%. The balance between equity and debt is satisfactory. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 3.3 years of cash flow to repay all financial debt. This ratio remains within usual banking standards. Cash flow represents 254.0% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.
153.044%
32.246%
254.001%
3.339
30.4%
In 2024, the debt ratio of CANCROISSANCE (153.04) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2024, the financial autonomy of CANCROISSANCE (32.2%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2024, the repayment capacity of CANCROISSANCE (3.34) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 1200.50. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 414.9x. Operating income very largely covers interest expenses: high safety margin.
1200.501
414.898
In 2024, the liquidity ratio of CANCROISSANCE (1200.50) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
In 2024, the interest coverage of CANCROISSANCE (414.9x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 1248 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 108 days. The gap of 1140 days means the company finances its customers for over a month before being paid relative to supplier payments. This weighs on cash flow. Overall, WCR represents 2098 days of revenue, i.e. 11.5 M€ to permanently finance. Over 2015-2024, WCR increased by +172%, requiring additional financing.
11 461 590 €
1248 j
108 j
0 j
2098 j
Based on 54 transactions of similar company sales
in 2024,
the value of CANCROISSANCE is estimated at
2 229 736 €
(range 1 261 513€ - 8 919 048€).
With an EBITDA of 136 948€, the sector multiple of 4.8x is applied.
The price/revenue ratio is 0.59x
(in line with sector norms).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.
Ajustez les pondérations selon votre analyse
This estimate is based on the analysis of 54 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare CANCROISSANCE with other companies in the same sector:
Voir toutes les statistiques du secteur Activités des sociétés holding
The revenue of CANCROISSANCE in 2024 is 2.0 M€.
Yes, CANCROISSANCE generated a net profit of 5.3 M€ in 2024.
The headquarters of CANCROISSANCE is located in MIRMANDE (26270), in the department Drome.
The tax return of CANCROISSANCE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
CANCROISSANCE operates in the sector Activités des sociétés holding (NAF code 64.20Z). See the 'Sector positioning' section above to compare the company with its competitors.